Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | The management of DLBCL and the importance of characterizing molecular subtypes

Gerardo Musuraca • 24 Oct 2022
SOHO Italy 2022
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Cyclophosphamide Doxorubicin Hyper-CVAD Prednisone R-CHOP Rituximab Vincristine

Gerardo Musuraca, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy, discusses the management of diffuse large B-cell lymphoma (DLBCL), highlighting the role of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) chemotherapy. Dr Musuraca further evaluates the importance of investigating new combination approaches to treat various molecular subtypes of DLBCL. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Gerardo Musuraca

1:12
Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agents
Gerardo Musuraca • 24 Oct 2022
2:34
Evolving treatment landscape of DLBCL
Gerardo Musuraca • 17 Sep 2020
2:19
Italian perspective: managing DLBCL
Gerardo Musuraca • 17 Sep 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals